Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 3, 2005, Pages 333-342

  Grossini, Elena ^a   Caimmi, P P ^b   Molinari, C ^a   Teodori, G ^b   Vacca, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Anesthetized pigs; Coronary blood flow; Intracoronary administration; Levosimendan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; LEVOSIMENDAN; MUSCARINIC RECEPTOR; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE; HEMODYNAMICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL;

ANESTHESIA; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD GAS ANALYSIS; CORONARY CIRCULATION; CORONARY VESSELS; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; HYDRAZONES; INFUSIONS, INTRAVENOUS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PYRIDAZINES; SWINE; VASODILATOR AGENTS;

EID: 24344455110     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000175435.41541.6f     Document Type: Article

References (41)

1. Lilleberg JM, Sundberg S, Hayha M, et al. Hemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol. 1994;47:267-274.
2. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan in severe low-output heart failure. Circulation. 1999; 100: I-646.
3. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222-2227.
4. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs. 2001;61:613-627.
5. Jamali IN, Kersten JR, Pagel PS, et al. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg. 1997; 85:23-29.
6. Kaheinen P, Pollesello P, Levijoski J, et al. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37:367-374.
7. Haikala H, Kaivola J. Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, Levosimendan. J Mol Cell Cardiol. 1995;27:1859-1866.
8. 2+], in guinea pig isolated ventricular myocytes. Eur J Pharmacol. 1997;339:97-100.
9. Pieske B. Levosimendan in regional myocardial ischemia. Cardiovasc Drugs Ther. 2002;16:379-381.
10. ATP channels. Anesth Analg. 2000;90:5-11.
11. + channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-259.
12. Bodi A, Szilagyi S, Edes I, et al. The cardiotonic effects of levosimendan in guinea pig hearts are modulated by beta-adrenergic stimulation. Gen Physiol Biophys. 2003;22:313-327.
13. Harkin CP, Pagel PS, Tessmer JP, et al. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol. 1995;26:179-188.
14. Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther. 2000;14:271-281.
15. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg. 2002;94:1427-1433.
16. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol. 1998;31:741-749.
17. Labriola C, Siro-Brigiani M, Carrata F, et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther. 2004;42:204-211.
18. Tassani P, Schad H, Heimish W, et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther. 2002;16:435-441.
19. Linden RJ, Mary DASG. The preparation and maintenance of anaesthetized animals for the study of cardiovascular functions. In: Linden RJ, ed. Life Sciences: vol P3/1, Techniques in Cardiovascular Physiology. Ireland: Elsevier Science Publisher, 1983:1-22.
20. Vacca G, Battaglia A, Grossini E, et al. The effect of 17β-oestradiol on regional blood flow in anaesthetized pigs. J Physiol. 1999;514:875-884.
21. Molinari C, Battaglia A, Grossini E, et al. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol. 2002; 543:365-372.
22. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J. 1997; 18:736-753.
23. Study Research Group PROMISE, Packer M, Carver JR, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
24. Hampton JR, Van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine in patients with advanced severe heart failure. Lancet. 1997;349:971-977.
25. Ver Donck J. Calcium-sensitizing drugs: positive inotropy by enhanced sensitivity of the contractile apparatus to calcium. Cardiovasc Drugs Rev. 1996;14:185-212.
26. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. J Biol Chem. 1994;269:28584-28590.
27. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
28. Holubarsch C. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology. 1997;88(Suppl 2):12-20.
29. Haikala H, Kaheinen P, Levijoki J, et al. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997;34:536-546.
30. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794-801.
31. Feigl EO. Coronary physiology. Physiol Rev. 1983;63:1-205.
32. 2+ sensitivity of cardiac myofibrils and sarcoplastic reticulum in guinea pig heart. Circ Res. 1995;77:107-113.
33. Gregory NG, Wotton SB. Autonomie and non-autonomic control of cardiovascular function in stress-sensitive pigs. J Vet Pharmacol Ther. 1981; 4:183-191.
34. Parent R, Paré R, Lavallé M. Contribution of NO to dilation of resistance coronary vessels in conscious dogs. Am J Physiol. 1992;262:H10-H16.
35. Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368:850-853.
36. + channels. Proc Natl Acad Sci USA. 1996;93: 10489-10494.
37. Murphy ME, Brayden JE. Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol. 1995;486:47-58.
38. Nelson MT, Patlak JB, Worley JF, et al. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol. 1990;259:C3-C18.
39. ATP channels. Circ Res. 1999;85:634-642.
40. Ca channels. Hypertension. 2003;41:912-918.
41. Miura T, Miki T. ATP-sensitive K1 channel openers: old drugs with new clinical benefits for the heart. Curr Vasc Pharmacol. 2003;1:251-258.